These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30770534)

  • 41. [Tetravaccine--new fundamental approach to prevention of influenza pandemic].
    Onishchenko GG; Zverev VV; Katlinskiĭ AV; Semchenko AV; Korovkin SA; Mel'nikov SIa; Mironov AN
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):15-9. PubMed ID: 17882832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.
    Levine MZ; Martin JM; Gross FL; Jefferson S; Cole KS; Archibald CA; Nowalk MP; Susick M; Moehling K; Spencer S; Chung JR; Flannery B; Zimmerman RK
    Clin Vaccine Immunol; 2016 Oct; 23(10):831-839. PubMed ID: 27558294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
    Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A;
    Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy.
    Bellino S; Bella A; Puzelli S; Di Martino A; Facchini M; Punzo O; Pezzotti P; Castrucci MR; The InfluNet Study Group
    Expert Rev Vaccines; 2019 Nov; 18(11):1201-1209. PubMed ID: 31674847
    [No Abstract]   [Full Text] [Related]  

  • 47. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.
    Khurana S; Hahn M; Coyle EM; King LR; Lin TL; Treanor J; Sant A; Golding H
    Nat Commun; 2019 Jul; 10(1):3338. PubMed ID: 31350391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.
    Liebowitz D; Gottlieb K; Kolhatkar NS; Garg SJ; Asher JM; Nazareno J; Kim K; McIlwain DR; Tucker SN
    Lancet Infect Dis; 2020 Apr; 20(4):435-444. PubMed ID: 31978354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.
    Keitel WA; Jackson LA; Edupuganti S; Winokur PL; Mulligan MJ; Thornburg NJ; Patel SM; Rouphael NG; Lai L; Bangaru S; McNeal MM; Bellamy AR; Hill HR;
    J Infect Dis; 2015 Aug; 212(4):552-61. PubMed ID: 25649171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults.
    Eiden J; Fierro C; Schwartz H; Adams M; Ellis KJ; Aitchison R; Herber R; Hatta Y; Marshall D; Moser MJ; Belshe R; Greenberg H; Coelingh K; Kawaoka Y; Neumann G; Bilsel P
    J Infect Dis; 2022 Dec; 227(1):103-112. PubMed ID: 36350017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
    Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
    Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses.
    Wang Z; Kedzierski L; Nuessing S; Chua BYL; Quiñones-Parra SM; Huber VC; Jackson DC; Thomas PG; Kedzierska K
    J Gen Virol; 2016 Dec; 97(12):3205-3214. PubMed ID: 27902386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers.
    Krairittichai U; Chittaganpitch M
    J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S1-7. PubMed ID: 23682516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-exposure with influenza A virus A/WSN/1933(H1N1) resulted in viral shedding reduction from pigs challenged with either swine H1N1 or H3N2 virus.
    Wang Z; Yu J; Thomas M; Sreenivasan CC; Hause BM; Wang D; Francis DH; Kaushik RS; Li F
    Vet Microbiol; 2019 Jan; 228():26-31. PubMed ID: 30593376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals.
    Rondy M; Launay O; Puig-Barberà J; Gefenaite G; Castilla J; de Gaetano Donati K; Galtier F; Hak E; Guevara M; Costanzo S; ; Moren A
    Euro Surveill; 2015 Jan; 20(2):. PubMed ID: 25613779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).
    Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F;
    Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.
    Hauge S; Madhun A; Cox RJ; Haaheim LR
    Clin Vaccine Immunol; 2007 Aug; 14(8):978-83. PubMed ID: 17596426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ineffectiveness of the 2014-2015 H3N2 influenza vaccine.
    Mandelboim M; Glatman-Freedman A; Drori Y; Sherbany H; Pando R; Sefty H; Zadka H; Shohat T; Keller N; Mendelson E
    Oncotarget; 2016 Jan; 7(2):1185-92. PubMed ID: 26716420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.